TRACT Therapeutics
TRACT Therapeutics is dedicated to developing innovative, personalized cellular therapies to improve transplant medicine and autoimmune disease treatment. Their flagship product, TregCel™, utilizes a patient's own regulatory T cells to establish immune tolerance, potentially reducing or eliminating the need for lifelong immunosuppressive drugs. The company aims to enhance long-term organ transplant success and treat autoimmune disorders, with ongoing clinical trials and strategic partnerships to advance their technology.
Industries
Nr. of Employees
small (1-50)
TRACT Therapeutics
Chicago, Illinois, United States, North America
Products
Autologous regulatory T cell therapeutic (autologous Treg product)
A personalized cell therapy derived from a patient's own regulatory T cells that are isolated, expanded ex vivo, cryopreserved if needed, and administered by IV infusion to promote immune tolerance in organ transplantation and autoimmune disease.
TRK-001
A personalized regulatory T cell therapy product consisting of a patient's own regulatory T cells expanded in a laboratory and infused as a single dose to establish immune tolerance in solid organ transplant and autoimmune disease patients.
Autologous regulatory T cell therapeutic (autologous Treg product)
A personalized cell therapy derived from a patient's own regulatory T cells that are isolated, expanded ex vivo, cryopreserved if needed, and administered by IV infusion to promote immune tolerance in organ transplantation and autoimmune disease.
TRK-001
A personalized regulatory T cell therapy product consisting of a patient's own regulatory T cells expanded in a laboratory and infused as a single dose to establish immune tolerance in solid organ transplant and autoimmune disease patients.
Services
Sponsorship and conduct of early-phase clinical studies in organ transplant and autoimmune indications, including safety monitoring and biomarker evaluation.
Transfer of manufacturing processes and platform know-how to external manufacturing facilities to support scale-up and trial advancement.
Development and implementation of streamlined manufacturing workflows for autologous Treg products, including selection, expansion, and final product shipping.
Sponsorship and conduct of early-phase clinical studies in organ transplant and autoimmune indications, including safety monitoring and biomarker evaluation.
Transfer of manufacturing processes and platform know-how to external manufacturing facilities to support scale-up and trial advancement.
Development and implementation of streamlined manufacturing workflows for autologous Treg products, including selection, expansion, and final product shipping.
Expertise Areas
- Regulatory T cell (Treg) adoptive cell therapy development
- Autologous cell therapy manufacturing and scale-up
- Early-phase clinical trial design and execution (cell therapy)
- Translational transplant immunology
Key Technologies
- Treg adoptive cell transfer
- Leukapheresis collection
- Ex vivo cell expansion
- Polyclonal Treg expansion to high-dose formulations
News & Updates
Announcement of successful technology transfer to Taiwan Bio's manufacturing facility.
Announcement of a poster presentation at the American Transplant Congress 2024.
Announcement of a new strategic partnership to advance Phase 2 trial in living donor kidney transplant.
Early clinical success in organ transplantation
Phase 1 clinical trial demonstrated safety and no rejection in kidney transplant patients.
Orphan Drug Designation for TregCel™
Granted for the prevention of graft rejection following solid organ transplantation.
Announcement of successful technology transfer to Taiwan Bio's manufacturing facility.
Announcement of a poster presentation at the American Transplant Congress 2024.
Announcement of a new strategic partnership to advance Phase 2 trial in living donor kidney transplant.
Early clinical success in organ transplantation
Phase 1 clinical trial demonstrated safety and no rejection in kidney transplant patients.
Orphan Drug Designation for TregCel™
Granted for the prevention of graft rejection following solid organ transplantation.